

Reference Number: FOIAH2324/621
From: Commercial
Date: 06 February 2024
Subject: How many patients have been treated with listed drugs

Q1 How many patients have been treated with the following drugs in the past 4 months:

- Atogepant (Aquipta) – any disease
- Erenumab (Aimovig) - any disease
- Eptinezumab (Vyepi) – any disease
- Fremanezumab (Ajoovy) - any disease
- Galcanezumab (Emgality) - any disease
- Rimegepant (Vydura) – any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

A1 The Trust do not stock the drugs listed, except Botox. No neurology patients have been prescribed or received Botox medication for migraines.

Q2 How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (4-15 headache days per month)
Atogepant		
Erenumab		
Eptinezumab		
Fremanezumab		
Galcanezumab		
Rimegepant		
Botulinum Toxin		

A2 Zero

Q3 Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

A3 These drugs are not used by the Trust.